MPOWERED Trial Open-Label Extension: Long-Term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.
Maria FleseriuMark E MolitchAlexander DrevalYulia PokramovichIrina BondarYury PoteshkinDjuro MacutBarbara Obermayer-PietschYossi Gilgun-SherkiAsi HavivNienke BiermaszChristian J StrasburgerPublished in: The Journal of clinical endocrinology and metabolism (2023)
Patient-reported outcome data support for the first time that transitioning patients randomized to iSRL (who previously responded to both OOC and iSRLs) back to OOC, had significant effect on patients' symptoms score in a prospective cohort. The MPOWERED OLE showed long-term maintenance of response and sustained safety with OOC.
Keyphrases
- patient reported outcomes
- open label
- end stage renal disease
- ejection fraction
- newly diagnosed
- phase iii
- phase ii
- chronic kidney disease
- clinical trial
- electronic health record
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- artificial intelligence
- depressive symptoms
- radiation therapy
- squamous cell carcinoma
- patient reported
- placebo controlled
- data analysis
- neuroendocrine tumors